Affordable Care Act
An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.
The organization plans to publish a scientific and a lay abstract detailing study findings
More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.
The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.
These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.
The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.
With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.
The March 31 deadline for health insurance is not the be-all-and-end-all, while a survey found that 50% of the uninsured intend to stay that way.
The program has yet to reach magnet status among cheaper, youthful patients.
Eli Lilly and Boehringer Ingelheim submit a glargine biosimilar to the EMA; Novartis pipeline claims an Enbrel-superior treatment; Activartis med gets orphan drug status; generics makers may have to pay more attention to labels; Administration tweaks healthcare reform implementation over the long weekend.
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
Amgen and Astellas team up to take on Japan; GSK acquires Swiss vaccine developer's innovative platform; Ireland makes generic switches easier; Novo backs wet AMD therapy; Nike ditches Livestrong
The agency is revisiting the impact DTC advertising can have on healthcare. What's new: NPs and PAs are being asked for input.
From FDA and pharma, to Caronia and off-label communication, three healthcare policy experts offer their take on what 2013 holds in store.
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
No sector of the healthcare industry is rooting harder for the Supreme Court to overturn the Affordable Care Act completely tomorrow than are medical device companies, which are bracing themselves for a substantial excise tax on their revenues that takes effect next year under the law.
Congressional Republicans are trumpeting a cache of emails that give a glimpse into how the White House's deal with the pharma industry on healthcare reform came together. There's not much 'there' there, but there are some titillating glimpses into the legislative sausage factory.
Congressional Republicans -- and even a few Democrats -- are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.